VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company stated that the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
This development is significant because sepsis is a life-threatening condition that requires rapid diagnosis and treatment. Current testing often relies on venous blood samples and laboratory equipment, which may not be readily available in remote or resource-limited settings. A finger-prick test could enable quicker, more accessible screening, potentially improving patient outcomes. For more details, the full press release is available at https://ibn.fm/ioEmu.
VolitionRx is focused on advancing epigenetics to develop simple, cost-effective blood tests for early detection and monitoring of diseases, including cancers and conditions associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S., as well as an office in London. Further information about Volition can be found on its website at www.Volition.com.
The implications of this announcement extend beyond sepsis. The ability to detect nucleosomes from capillary blood using a lateral flow test could pave the way for decentralized testing of other diseases, potentially reducing the burden on centralized laboratories and enabling more widespread screening. This aligns with global health efforts to bring diagnostic capabilities closer to patients, particularly in underserved areas.
VolitionRx’s progress in this area may also attract potential partners interested in expanding access to diagnostics in regions with limited infrastructure. The company’s focus on commercialization and partnerships suggests a strategic move to bring this technology to market, which could have a significant impact on public health.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VolitionRx Achieves Finger-Prick Breakpoint for Nucleosome Detection in Sepsis.